Reata Pharms Drug Patent Portfolio

Reata Pharms owns 1 orange book drug protected by 7 US patents Given below is the list of Reata Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8993640 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof 24 Apr, 2033
Active
US9701709 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof 24 Apr, 2033
Active
US8124799 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 03 Dec, 2029
Active
US11091430 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 20 Apr, 2029
Active
US11919838 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 20 Apr, 2029
Active
US8440854 Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 20 Apr, 2029
Active
US9670147 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 20 Apr, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Reata Pharms.

Activity Date Patent Number
Patent litigations
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8993640
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8440854
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9701709
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8124799
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9670147
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US11091430
Recordation of Patent Grant Mailed 05 Mar, 2024 US11919838
Patent eGrant Notification 05 Mar, 2024 US11919838
Mail Patent eGrant Notification 05 Mar, 2024 US11919838
Email Notification 05 Mar, 2024 US11919838
Patent Issue Date Used in PTA Calculation 05 Mar, 2024 US11919838
Recordation of Patent eGrant 05 Mar, 2024 US11919838
Email Notification 15 Feb, 2024 US11919838
Issue Notification Mailed 14 Feb, 2024 US11919838
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US8124799


Reata Pharms's Family Patents

Reata Pharms drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Reata Pharms Drug List

Given below is the complete list of Reata Pharms's drugs and the patents protecting them.


1. Skyclarys

Skyclarys is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8993640 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof 24 Apr, 2033
(8 years from now)
Active
US9701709 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof 24 Apr, 2033
(8 years from now)
Active
US8124799 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 03 Dec, 2029
(4 years from now)
Active
US11091430 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 20 Apr, 2029
(4 years from now)
Active
US11919838 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 20 Apr, 2029
(4 years from now)
Active
US8440854 Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 20 Apr, 2029
(4 years from now)
Active
US9670147 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 20 Apr, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Skyclarys's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List